Migraine is one of the most common medical diagnoses, affecting 13% of adult population, or 1 in 4 households, in the U.S [1] . Migraines frequently occur between 25 and 55 years of age, resulting in major limitations on quality of life and economic opportunity during our most generative years of life. The societal and economical implications include 112 million bedridden days per year and costs exceeding over $15 billion due to work loss [2] . Despite their prevalence and burden, migraines remain a sorely underdiagnosed and undertreated disability [1] .
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In Wilmhurst and colleagues' seminal trial [3] , migraine relief was a serendipitous finding in select patients who underwent patent foramen ovale (PFO) closure for decompression illness and stroke. Similar findings in multiple retrospective cohorts [4] [5] [6] spurred the field to focus its sights on PFO closure in the setting of cryptogenic stroke.
A provocative, albeit opaque, relationship emerged between right-to-left shunt (RLS), migraines, and PFO closure. Cryptogenic stroke patients were twice as likely to have a history of migraine headaches as those without PFO (27% versus 14%, respectively) [7] . PFO was seen more frequently in people with migraine with aura than in age-and sex-matched controls (47% versus 17%, respectively) [8] . Headache activation after atrial septal defect (ASD) closure, specifically with Nitinol-based devices (Amplatzer), was reported, encouraging further investigation [9, 10] . All that was necessary was a prospective clinical trial, designed to account for the placebo effect and adjudicated by migraine neurologists: the Migraine Intervention with StarFlex Technology (MIST) trial [11] .
Many interventional cardiologists were optimistic; we saw dramatic life changes in our patients. Otherwise healthy individuals with cryptogenic stroke who were debilitated, not by residual neurological defects, but by crippling migraine headaches, returned to our clinics months later reporting life-altering improvements in headache frequency and severity.
The construct collapsed with a negative trial, critiqued for its design, operators, patient selection, marginally effective device, and overreaching endpoint. Perhaps we should have predicted the study outcome based solely on the ubiquitous nature of headache. We did not have a pathologic footprint to track, which remains true to this day. It was known that migraine is an elusive target for phar- Letter to the Editor 232 macological therapy; this held true for devices as well. These challenges culminated in the termination of MIST II. Despite these setbacks, investigators have continued to explore the closure of interatrial septal defects and migraine relief. The study by Tayaka and colleagues [12] provides another link between the presence of RLS and migraines. Their data support the reports of a higher prevalence (56%) of migraines in patients with RLS, but also suggest a high prevalence in patients with ASDs (29%). While not an entirely novel finding, the relationship behind ASD and migraines has not been the emphasis of investigation. This prospective trial adds little to the body of evidence of nonrandomized PFO closure and migraine relief, but it demonstrates that there is potentially an interaction with ASDs, and their closure may impact headaches.
The study by Tayaka et al addresses several gaps of previous trials. The endpoint assessment of headache was based, correctly, on a neurologist's evaluation. The four-category reporting system for headache severity and frequency provides quantification consistent with the real world expectation of improvement. Follow-up was well documented, along with the response to clopidogrel, which may play a role in migraine relief. Notably, relief persisted beyond the termination of clopidogrel at 1 month.
The trial exhibits well-described limitations of nonrandomized clinical studies without control groups or blinding. The assessment of pharmacologic therapy for migraine headache was not described, and the evaluation tools did not include a headache diary. These omissions are especially important given that improvement, and specifically complete resolution, of migraines was high in all patients. Migraine relief was highest in patients after PFO closure but also high after ASD closure, with 15 of 20 patients improving and nearly half of these patients reporting complete resolution. The mean post-procedure follow-up for patients after ASD closure was half of that after PFO closure (22 versus 44 months, respectively). A longer follow-up period overall may have decreased the likelihood that relief was due to placebo and would have been beneficial to evaluate the underlying relationship between RLS and headache.
Tayaka and colleagues did not specify key methods and procedures, including the imaging protocol for evaluating interatrial septal defect anatomy and RLS. Thus, procedural success was not defined. Related procedural results were undescribed, namely the presence and quantitation of post-procedural residual shunt in patients after ASD closure, particularly in those without improvement of migraine. These descriptions and data are critical to correlating closure with relief, and particularly essential in the study of a clinical syndrome with placebo effects that may exceed 20% [13] .
A large, randomized clinical trial aimed to overcome these limitations and provide a definitive foundation for evidence-based PFO closure for migraine headache. The Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the Amplatzer PFO Occluder to Medical Management (PREMIUM) trial was presented in June 2015 at the American Headache Society [14] . PREMIUM was the third trial to examine migraine relief with PFO closure, the second to use the Amplatzer device, and the second to use sham surgery as a control. The primary endpoint of 50% reduction in migraine was not met; there was no difference in migraine attack frequency in patients who underwent closure (n = 117) versus patients randomized to sham and medical therapy (n = 103). Among migraineurs with aura, however, those in the closure group had a higher rate of complete remission than those in the sham group (10.8% versus 1.5%, p = 0.02).
These results are consistent with the compelling body of literature demonstrating migraine relief after PFO closure in the subset of patients who have migraine with aura. The high frequency of large RLS in these patients [8] , and the high rate of migraine relief and even complete remission in patients after PFO closure [12, 14] , suggest that RLS has a role in migraine pathogenesis. However, study findings must be cautiously interpreted before changing clinical practice. Currently, there are no studies actively enrolling for PFO closure in patients with headache, and it is purported that the U.S. Food & Drug Administration may want another trial. Fundamental questions for future investigation remain.
• In the absence of a pathologic signature, can we refine Reisman, M. et al.
Migraine and Interatrial Septal Defects our study group in subsequent randomized trials?
• Based on the safety of PFO devices [15] , is it reasonable to address a cohort with headaches less recalcitrant than migraine? • Can we define a PFO or RLS headache? Are there other substrates lacking chemical conversion by the pulmonary circulation in these patients?
In conclusion, Tayaka and colleagues have deepened our knowledge base. However, investigators must expand our inquiry to the basic science linking right-to-left circulation and headaches. Migraines are one of the most debilitating diseases, and, if a safe and simple cardiac procedure is to be provided in hopes of improving our patient's health and quality of life in their prime, it is imperative that we cement the construct between migraine, RLS, and this therapy.
